Cellular Immune Responses to BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

Background: Patients with chronic lymphocytic leukemia (CLL) are known to have a suboptimal immune response of both humoral and cellular arms. Recently, a BNT162b2 mRNA COVID-19 vaccine was introduced with a high efficacy of 95% in immunocompetent individuals. Approximately half of the patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Itchaki, Gilad, Rokach, Lior, Benjamini, Ohad, Bairey, Osnat, Sabag, Adi, Vernitsky, Helly, Cohen, Hila, Rotem, Shahar, Elia, Uri, Raanani, Pia, Bar-Haim, Erez, Tadmor, Tamar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
642.Chronic Lymphocytic Leukemia: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701652/
http://dx.doi.org/10.1182/blood-2021-150796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701652/
http://dx.doi.org/10.1182/blood-2021-150796

Ejemplares similares